DNLI
Price
$15.34
Change
-$0.21 (-1.35%)
Updated
Aug 27, 11:19 AM (EDT)
Capitalization
2.27B
64 days until earnings call
OCUL
Price
$12.31
Change
-$0.01 (-0.08%)
Updated
Aug 27, 11:36 AM (EDT)
Capitalization
2.14B
75 days until earnings call
Interact to see
Advertisement

DNLI vs OCUL

Header iconDNLI vs OCUL Comparison
Open Charts DNLI vs OCULBanner chart's image
Denali Therapeutics
Price$15.34
Change-$0.21 (-1.35%)
Volume$900
Capitalization2.27B
Ocular Therapeutix
Price$12.31
Change-$0.01 (-0.08%)
Volume$1.05K
Capitalization2.14B
DNLI vs OCUL Comparison Chart in %
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. OCUL commentary
Aug 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Buy and OCUL is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 27, 2025
Stock price -- (DNLI: $15.55 vs. OCUL: $12.32)
Brand notoriety: DNLI and OCUL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 127% vs. OCUL: 80%
Market capitalization -- DNLI: $2.27B vs. OCUL: $2.14B
DNLI [@Biotechnology] is valued at $2.27B. OCUL’s [@Biotechnology] market capitalization is $2.14B. The market cap for tickers in the [@Biotechnology] industry ranges from $99.27B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileOCUL’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • OCUL’s FA Score: 0 green, 5 red.
According to our system of comparison, OCUL is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 5 TA indicator(s) are bullish while OCUL’s TA Score has 2 bullish TA indicator(s).

  • DNLI’s TA Score: 5 bullish, 4 bearish.
  • OCUL’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than OCUL.

Price Growth

DNLI (@Biotechnology) experienced а +5.03% price change this week, while OCUL (@Biotechnology) price change was +1.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.96%. For the same industry, the average monthly price growth was +13.89%, and the average quarterly price growth was +31.16%.

Reported Earning Dates

DNLI is expected to report earnings on Oct 30, 2025.

OCUL is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+3.96% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.27B) has a higher market cap than OCUL($2.14B). OCUL YTD gains are higher at: 44.262 vs. DNLI (-23.700). OCUL has higher annual earnings (EBITDA): -200.5M vs. DNLI (-521.52M). DNLI has more cash in the bank: 899M vs. OCUL (391M). DNLI has less debt than OCUL: DNLI (46.6M) vs OCUL (76.9M). OCUL has higher revenues than DNLI: OCUL (56.7M) vs DNLI (0).
DNLIOCULDNLI / OCUL
Capitalization2.27B2.14B106%
EBITDA-521.52M-200.5M260%
Gain YTD-23.70044.262-54%
P/E RatioN/AN/A-
Revenue056.7M-
Total Cash899M391M230%
Total Debt46.6M76.9M61%
FUNDAMENTALS RATINGS
DNLI vs OCUL: Fundamental Ratings
DNLI
OCUL
OUTLOOK RATING
1..100
1158
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
54
Fair valued
PROFIT vs RISK RATING
1..100
10083
SMR RATING
1..100
9698
PRICE GROWTH RATING
1..100
5438
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
1050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OCUL's Valuation (54) in the Pharmaceuticals Other industry is somewhat better than the same rating for DNLI (93) in the Biotechnology industry. This means that OCUL’s stock grew somewhat faster than DNLI’s over the last 12 months.

OCUL's Profit vs Risk Rating (83) in the Pharmaceuticals Other industry is in the same range as DNLI (100) in the Biotechnology industry. This means that OCUL’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (96) in the Biotechnology industry is in the same range as OCUL (98) in the Pharmaceuticals Other industry. This means that DNLI’s stock grew similarly to OCUL’s over the last 12 months.

OCUL's Price Growth Rating (38) in the Pharmaceuticals Other industry is in the same range as DNLI (54) in the Biotechnology industry. This means that OCUL’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's P/E Growth Rating (98) in the Biotechnology industry is in the same range as OCUL (100) in the Pharmaceuticals Other industry. This means that DNLI’s stock grew similarly to OCUL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIOCUL
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
76%
Momentum
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
85%
MACD
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 6 days ago
80%
Declines
ODDS (%)
Bearish Trend 8 days ago
80%
Bearish Trend 8 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
76%
N/A
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ANVIX28.84N/A
N/A
Virtus NFJ Large-Cap Value Fund Inst
CSCCX27.26N/A
N/A
Calvert Small-Cap C
PRJIX55.32N/A
N/A
T. Rowe Price New Horizons I
FNGDX16.63N/A
N/A
Franklin Intl Growth C
TOWFX17.52N/A
N/A
Towpath Focus Institutional

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with NRIX. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-0.13%
NRIX - DNLI
58%
Loosely correlated
-1.45%
BEAM - DNLI
58%
Loosely correlated
+1.22%
ARWR - DNLI
58%
Loosely correlated
+2.27%
OCUL - DNLI
54%
Loosely correlated
+3.79%
RGNX - DNLI
53%
Loosely correlated
+1.67%
More

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with EYPT. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
+3.79%
EYPT - OCUL
65%
Loosely correlated
+3.88%
IDYA - OCUL
55%
Loosely correlated
+0.61%
DNLI - OCUL
55%
Loosely correlated
-0.13%
CRNX - OCUL
55%
Loosely correlated
+2.79%
RVMD - OCUL
55%
Loosely correlated
+4.50%
More